12 gene therapies converge on retinitis pigmentosa and a $3.4bn market by 2033
This month Gene Scope Intelligence (www.genescope-intelligence.com), a dedicated gene therapy market intelligence platform releases a brand new commercial analysis and demand forecast for new gene therapies directed at Retinitis Pigmentosa (RP).
Gene therapies for wet AMD: reshaping the blockbuster anti‑VEGF market
This month, VacZine Analytics, a specialist publisher in healthcare commercial analysis, releases a brand-new global forecast focused on new gene therapies for Wet age-related macular degeneration (wet AMD).
Why gene therapy matters now
This month, VacZine Analytics, a specialist publisher in healthcare commercial analysis, releases a brand-new situation review on the FDA approved "classical" gene therapy landscape.
Norovirus vaccines - closer than you think
This month VacZine Analytics, a specialist in infectious diseases and vaccines commercial analysis, publishes a brand-new global demand assessment for new norovirus vaccines.
Acne vulgaris vaccines: time for something new
This month VacZine Analytics, a specialist in infectious diseases and vaccines commercial analysis, publishes a brand-new global analysis focused on the potential for acne vulgaris vaccines.
Takeda’s Qdenga® - more campaigns needed before single-dose products arrive
This month VacZine Analytics, a specialist in infectious diseases and vaccines commercial analysis publishes a brand-new global analysis of the dengue endemic vaccines market.
mRNA influenza vaccines – VacZine Analytics forecast a third of global market value in 2030
This month VacZine Analytics, a specialist in infectious diseases and vaccines commercial analysis publishes a brand-new global analysis of the seasonal influenza vaccine market including mRNA products (monovalent and combinations)
Group B Streptococcus vaccines - not just for the baby
This month VacZine Analytics, a specialist in infectious diseases and vaccines commercial analysis publishes a brand-new global demand assessment for Group B Streptococcus (GBS) vaccines.
New travel vaccines - more protection but more cost and complexity
This month VacZine Analytics, a UK-based strategic research publisher exclusively focused on vaccines and infectious diseases, releases a review of the global travel vaccine segment. 9 new products, including those for dengue and chikungunya viruses, are assessed for their potential to 2040. An informative survey to capture the viewpoints of travelers' is also included in the research study.
RSV older adult, elderly vaccines - durability versus combination?
This month VacZine Analytics, a UK-based strategic research publisher exclusively focused on vaccines and infectious diseases, releases a new updated global demand analysis for RSV older adult, elderly vaccines.
Klebsiella pneumoniae vaccines - time to reprioritize
This month VacZine Analytics, a UK-based strategic research publisher exclusively focused on vaccines and infectious diseases, releases a brand-new global forecast of new Klebsiella pneumoniae vaccines.
Can mRNA bring its magic to seasonal influenza vaccines?
This month VacZine Analytics, a UK-based strategic research publisher exclusively focused on vaccines and infectious diseases, releases a brand-new global forecast of seasonal influenza vaccines, and discusses the prospects for new mRNA candidates.
Herpes Simplex Virus vaccines - a much needed renaissance
This month VacZine Analytics, a UK-based strategic research publisher exclusively focused on vaccines and infectious diseases, releases new forecasts and global commercial opportunity analyses for prophylactic and therapeutic Herpes simplex virus (HSV) vaccines.
Nirsevimab and RSV: first choice or complementary choice?
This month VacZine Analytics, a UK-based strategic research publisher exclusively focused on vaccines and infectious diseases, releases a new forecast and global demand analysis for Respiratory Syncytial Virus (RSV) vaccines and monoclonals.
An Epstein-barr (EBV) vaccine: preventing downstream cancer risk and more....
This month VacZine Analytics, a UK-based strategic research publisher exclusively focused on vaccines and infectious diseases, releases a new forecast and global demand analysis for prophylatic and therapeutic Epstein-barr virus (EBV) vaccines.
Dengue endemic vaccines: awaiting Takeda's TAK-003
This month VacZine Analytics®, a UK-based strategic research publisher exclusively focused on vaccines and infectious diseases, releases a brand new global commercial forecast for dengue-endemic vaccines.
Congenital Cytomegalovirus vaccines - could it be the next HPV?
This month VacZine Analytics, a UK-based strategic research publisher exclusively focused on vaccines and infectious diseases, releases a new forecast and global demand analysis for congenital Cytomegalovirus (cCMV) vaccines.
COVID-19 vaccines and the seasonal scenario
This month VacZine Analytics, a UK-based strategic research publisher exclusively focused on vaccines and infectious diseases, releases a new updated ‘seasonal scenario’ global demand analysis for COVID-19 vaccines.
Respiratory virus vaccines - to dominate industry focus
This month VacZine Analytics, a UK-based strategic research publisher exclusively focused on vaccines and infectious diseases, releases a brand new analysis focused on the respiratory virus vaccine segment to 2035. Seven new potential vaccine products are covered.
Seasonal influenza vaccines - high on the global agenda
This month VacZine Analytics, a UK-based strategic research publisher exclusively focused on vaccines and infectious diseases, releases an updated global demand analysis for seasonal influenza vaccines.
Norovirus vaccines - time to rethink the market segments?
This month VacZine Analytics, a UK-based strategic research publisher exclusively focused on vaccines and infectious diseases, releases an updated global demand analysis for norovirus vaccines.
A novel coronavirus [COVID-19] vaccine - assessing future global demand
This month VacZine Analytics, a UK-based strategic research publisher exclusively focused on vaccines and infectious diseases, releases a brand-new global demand analysis for novel coronavirus [COVID-19] vaccines.
Chikungunya vaccines - only as and when needed....
This month VacZine Analytics, a UK-based strategic research publisher exclusively focused on vaccines and infectious diseases, releases a brand-new commercial assessment of Chikungunya vaccines. Relative to other healthcare priorities in affected countries, is a Chikungunya vaccine high on the list?
Norovirus vaccines - the bigger sequel to rotavirus?
This month VacZine Analytics, a UK-based strategic research publisher exclusively focused on vaccines and infectious diseases, releases a brand-new commercial assessment of norovirus vaccines.
Porphyromonas gingivalis vaccines - gum disease is just the beginning...
This month VacZine Analytics, a UK-based strategic research publisher exclusively focused on vaccines and infectious diseases, releases a brand-new commercial assessment of Porphyromonas gingivalis vaccines.